PubRank

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Clinical Trial ID NCT01336634

PubWeight™ 23.36‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01336634

Top papers

Rank Title Journal Year PubWeight™‹?›
1 New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013 2.25
2 Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 2015 1.29
3 Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol 2015 1.24
4 The MAPK pathway across different malignancies: a new perspective. Cancer 2014 1.22
5 Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther 2013 1.22
6 The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med 2013 1.18
7 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
8 Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol 2016 1.06
9 Review of the current targeted therapies for non-small-cell lung cancer. World J Clin Oncol 2014 1.05
10 Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol 2013 1.03
11 Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol 2013 1.02
12 Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 2016 1.02
13 Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015 0.97
14 Lung cancer in the era of precision medicine. Clin Cancer Res 2015 0.96
15 BRAF inhibitors in clinical oncology. F1000Prime Rep 2013 0.93
16 BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget 2014 0.92
17 Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? Ther Adv Med Oncol 2013 0.86
18 Recent advances in personalized lung cancer medicine. Per Med 2014 0.82
19 Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol 2016 0.79
20 Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. World J Clin Oncol 2013 0.79
21 New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics 2016 0.79
22 The minority report: targeting the rare oncogenes in NSCLC. Curr Treat Options Oncol 2014 0.78
23 BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib. Int J Clin Exp Pathol 2015 0.75
Next 100